AUG 25, 2020 8:20 AM PDT

Targeting Checkpoint Molecule Could Mean Checkmate for Cancer

WRITTEN BY: Tara Fernandez


In a new study published in Cell, researchers have identified a metabolic enzyme that could have powerful tumor-killing effects when targeted by immunotherapies. Interleukin-4-Induced-1, or IL4I1, is secreted in large quantities by tumors, naturally promoting the spread of cancers while simultaneously suppressing the immune system.

Immunotherapies are drug modality that works by either activating or quietening the immune system, helping the body to fight autoimmune conditions, infectious diseases, and cancer. For oncology applications, a variety of immunotherapies are currently available including T cell transfer therapies, monoclonal antibodies, cancer vaccines, and immune checkpoint inhibitors. While in theory, these approaches hold promise, clinical results have often fallen flat, leading researchers to identify fresh ways of boosting their efficacy on a molecular level.

IL4I1 was of particular interest to oncology researchers as a potential target because of its ability to promote cancer cell motility, dampen the adaptive immune response to cancer, and also its correlation with reduced survival in glioma (a malignant brain cancer) patients. The study’s authors saw similar observations in mouse models of glioma, as noted by study author Martina Seiffert from the German Cancer Research Center (DKFZ).

“In animals that do not produce IL4I1 in the tumor environment due to genetic alterations, the immune system is significantly more successful in preventing the cancer from progressing,” said Seiffert.

Their results put IL4I1 within the crosshairs as a prime target for future immunotherapies. As Christiane Opitz, a research group leader at DKFZ concludes, “IL4I1 has great potential as a target for drugs. So far, drugs that inhibit enzymes of the tryptophan metabolism have failed in clinical trials because the tumors did not respond to them. However, the role of IL4I1 has so far been disregarded, and this enzyme has not yet been tested as a target molecule.”

 

 

Sources: Cell, Genetic Engineering & Biotechnology News.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 06, 2020
Immunology
COVID Triggers Abnormalities in Immune Monocytes
OCT 06, 2020
COVID Triggers Abnormalities in Immune Monocytes
University of Manchester immunologists are the first to make an interesting observation about the white blood cells of p ...
OCT 15, 2020
Immunology
The Immune Cells Giving Menopausal Women Higher BPs
OCT 15, 2020
The Immune Cells Giving Menopausal Women Higher BPs
In general, men have higher blood pressures than women, giving them an increased risk of developing heart disease. After ...
NOV 05, 2020
Immunology
Immune cells from recovered COVID-19 patients can help protect immunocompromised individuals against infection
NOV 05, 2020
Immune cells from recovered COVID-19 patients can help protect immunocompromised individuals against infection
Our knowledge of COVID-19 or SARS-CoV-2 is increasing every day, with new research papers published continuously. Resear ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
NOV 19, 2020
Immunology
Parasitic Worms Help Unravel the Immune Mechanisms Underlying Chronic Disease
NOV 19, 2020
Parasitic Worms Help Unravel the Immune Mechanisms Underlying Chronic Disease
Parasitic worms known as helminths have a complicated relationship with the immune systems of the hosts they invade. Ter ...
JAN 06, 2021
Immunology
What's Causing Prostate Cancer Patients to Doze Off?
JAN 06, 2021
What's Causing Prostate Cancer Patients to Doze Off?
For prostate cancer patients, androgen deprivation therapy or ADT is a standard treatment aimed at stalling the growth o ...
Loading Comments...